<DOC>
	<DOCNO>NCT01757405</DOCNO>
	<brief_summary>The purpose study determine efficacy safety rFVIIa BI part six-month on-demand treatment regimen hemophilia A B subject inhibitor .</brief_summary>
	<brief_title>Recombinant Factor VIIa BI ( rFVIIa BI ) Treatment Acute Bleeding Episodes Per On-demand Regimen</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Main Participant male hemophilia A B inhibitor , high titer ( ≥5 Bethesda unit ( BU ) ) historical high anamnestic response . Participant 12 65 year old time screening . Participant currently use use bypass agent treatment bleed episode . Participant annualized bleed rate 5 bleeding episode per year average 2 year prior Screening visit . Participant Karnofsky Performance Score ≥60 . Participant hepatitis C virus negative ( HCV ) either antibody testing polymerase chain reaction ( PCR ) ; hepatitis C virus positive ( HCV+ ) stable hepatic disease . Participant human immunodeficiency virus negative ( HIV ) HIV+ stable disease , CD4+ count ≥200 cells/mm^3 screening . Participant willing able comply requirement protocol . Main Participant willing go ondemand treatment scheme . Participant positive FVII inhibitor screen . Participant clinically symptomatic liver disease . Participant platelet count &lt; 100,000/µL . The use αinterferon without ribavirin plan HCVinfected participant use protease inhibitor plan HIVinfected participant . Participants currently take medication ≥30 day eligible . Participant known hypersensitivity rFVIIa , hamster murine protein , Tween 80 . Participant known history nonresponsive rFVIIa treatment bleed episode . Participant prior history thromboembolic event diagnosis disease may increase participant 's risk thromboembolic complication . Participant participate another clinical study involve investigational product ( IP ) investigational device within 30 day prior enrollment schedule participate another clinical study involve IP investigational device course study . Participant family member employee investigator . Participant schedule surgery study period .</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Factor VIII ( FVIII ) Factor IX ( FIX ) inhibitor</keyword>
</DOC>